

Serial No. 09/719,410
Amylin Docket No.: 0206-UTL-9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

AMYLIN PHARMACEUTICALS, INC.

Applicants: Burkhard GOKE, et al.

Serial No.: 09/719,410

Filed: December 12, 2000

Title: GLUCAGON-LIKE PEPTIDE-1
IMPROVES THE ABILITY OF THE
 β -CELL TO SENSE AND RESPOND
TO GLUCOSE IN SUBJECTS WITH
IMPAIRED GLUCOSE TOLERANCE

Group Art Unit: 1623

Examiner: Abdel A. MOHAMED

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. §1.97(d), the articles and patent documents listed and identified on the attached Form PTO/SB/08 are being submitted after the mailing date of a final action under § 1.113. Accordingly, the statement specified under §1.97(e) and the fee set forth in §1.17(p) are submitted herewith.

Copies of the listed references are enclosed. The Examiner is requested to consider the references and make them of record.

02/25/2005 LWONDIM1 00000142 010535 09719410
01 FC:1806 180.00 DA

CERTIFICATE OF MAILING
(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit

2/17/05

Deborah Wykes

Name of Person Mailing Paper

Signature of Person Mailing Paper


Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

A fee of \$180.00 is believed due in connection with this communication. The Commissioner is hereby authorized to charge payment of this and any additional fees associated with this communication or credit any overpayment to Amylin Pharmaceuticals, Inc.'s Deposit Account No. 010535.

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.

Dated: 2/16/2005

By: 
Mi K. Kim
Registration No. 44,830

AMYLIN PHARMACEUTICAL, INC.
9360 Town Centre Drive
San Diego, CA 92121
Telephone: 858.552.2200
Facsimile: 858.552.1936

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/719,410
Filing Date	December 12, 2000
First Named Inventor	Burkhard Goke
Art Unit	1623
Examiner Name	A. Mohamed
Attorney Docket Number	0206-UTL-9

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/719,410
Filing Date	December 12, 2000
First Named Inventor	Burkhard Goke
Art Unit	1623
Examiner Name	A. Mohamed
Attorney Docket Number	0206-UTL-9

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	D'ALESSIO, D. A., et al., "Elimination of the Action of Glucagon-Like Peptide-1 Causes an Impairment of Glucose Tolerance After Nutrient Ingestion by Healthy Baboons" <i>JOURNAL OF CLINICAL INVESTIGATION</i> , (Jan 1996) 97 (1) 133-138.	
	2	RITZEL, U., et al., "A Synthetic Glucagon-Like Peptide-1 Analog With Improved Plasma Stability" <i>JOURNAL OF ENDOCRINOLOGY</i> , (Oct 1998) Bristol, GB, 159 (1) 93-102.	
	3	SCHIRRA, J., et al., "Exendin (9-39) Amide is an Antagonist of Glucagon-Like Peptide-1 (7-36) Amide in Humans" <i>JOURNAL OF CLINICAL INVESTIGATION</i> (Apr 1998) 101 (7) 1421-1430.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.